atorvastatin has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 192 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (7.81) | 18.2507 |
| 2000's | 116 (60.42) | 29.6817 |
| 2010's | 50 (26.04) | 24.3611 |
| 2020's | 11 (5.73) | 2.80 |
| Authors | Studies |
|---|---|
| Ferguson, E; Krause, BR; Newton, RS; Roth, BD; Shaw, MK; Sliskovic, DR | 1 |
| Roberts, WC | 1 |
| Baetta, R; Calore, M; Comparato, C; Donetti, E; Fumagalli, R; Paoletti, R; Rossi, A; Soma, MR; Teruzzi, C | 1 |
| Hunninghake, D; Jones, P; Kafonek, S; Laurora, I | 1 |
| Pincus, J | 1 |
| Bakker-Arkema, RG; Black, DM; Brown, AS; Campbell, CF; Guthrie, R; Henley, RW; Koren, M; McLain, R; Woo, W; Yellen, L | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
| Bakker-Arkema, RG; Black, DM; Davidson, MH; Henley, RW; Hunninghake, DB; Koren, MJ; McKenney, JM; McLain, RW; Schrott, HG; Smith, DG; Tresh, P; Weiss, SR | 1 |
| Assang, C; Baillie, TA; Lin, JH; Lu, P; Ma, B; Meng, Y; Prueksaritanont, T; Reider, PJ; Tang, C | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Branchi, A; Fiorenza, AM; Macor, S; Muzio, F; Rovellini, A; Sommariva, D; Torri, A | 1 |
| Farnier, M | 1 |
| Hoshi, K; Ichihara, K; Satoh, K; Yamamoto, A | 1 |
| Baetta, R; Bellosta, S; Bernini, F; Corsini, A; Fumagalli, R; Paoletti, R | 1 |
| Ichihara, K; Satoh, K | 1 |
| Chan, M; Giannetti, N; Hayashi, S; Hunt, SA; Kato, T; Kobayashi, T; Morimoto, S; Namii, Y; Tokoro, T; Yokoyama, I | 1 |
| Auch-Schwelk, W; Elsner, M; Mach, S; Schächinger, V; Walter, DH; Zeiher, AM | 1 |
| Arnaboldi, L; Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
| Dansette, PM; Jaoen, M; Pons, C | 1 |
| Bonardo, B; Juhan-Vague, I; Lopez, S; Nalbone, G; Peiretti, F | 1 |
| Cromwell, WC; Ziajka, PE | 1 |
| Ose, L; Risberg, K; Svilaas, A; Thoresen, M | 1 |
| Davidson, MH | 1 |
| Stein, EA | 2 |
| Crouch, MA | 1 |
| Harangi, M; Paragh, G | 1 |
| Rosenson, RS; Schaefer, EJ; Tangney, CC | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Maclaine, GD; Patel, H | 1 |
| Dimitroulakos, J; Minden, MD; Penn, LZ; Tan, MM; Wong, WW; Xia, Z | 1 |
| Wierzbicki, AS | 1 |
| Andrews, TC; Ballantyne, CM; Hsia, JA; Kramer, JH | 1 |
| Auer, J; Eber, B | 1 |
| Igel, M; Sudhop, T; von Bergmann, K | 1 |
| Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY | 1 |
| Bazalo, GR | 1 |
| Altamura, L; Chiariello, L; Crea, F; Gaspardone, A; Gioffrè, PA; Proietti, I; Tomai, F; Versaci, F | 1 |
| Aaronson, KD; Baliga, RR; Cody, RJ; Dyke, DB; Koelling, TM; Lake, KD; Pagani, FD; Patel, DN | 1 |
| Auteri, A; Bova, G; Bruni, F; Cercignani, M; Console, E; Palazzuoli, A; Pasqui, AL; Puccetti, L | 1 |
| Asztalos, BF; Horvath, KV; McNamara, JR; Roheim, PS; Rubinstein, JJ; Schaefer, EJ | 1 |
| Angori, P; Auteri, A; Bova, G; Bruni, F; Cercignani, M; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Fuller, S; Gillen, D; Lacey, L; Marriott, J; Wilson, K | 1 |
| McBurney, CR; Smith, DG | 1 |
| Clark, LT | 1 |
| Oguogho, A; Sinzinger, H | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Betz, W; Devroey, D; Duquet, W; Velkeniers, B | 1 |
| Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| Błaszczyk, J; Cegliński, T; Grycewicz, J; Irzmański, R; Kowalczyk, E; Kowalski, J; Pawlicki, L | 1 |
| Edwards, JE; Moore, RA | 1 |
| Mach, F | 1 |
| Andrus, MR | 1 |
| Horiuchi, S; Iida, KT; Matsuzaka, K; Nakagawa, Y; Nakakuki, M; Okazaki, H; Sakai, M; Sakamoto, Y; Shimano, H; Shu, M; Sone, H; Suzuki, H; Takahashi, A; Toyoshima, H; Yamada, N; Yokoo, T | 1 |
| Mück, AO; Seeger, H; Wallwiener, D | 2 |
| Mason, P | 1 |
| Bell, PR; Loftus, IM; Molloy, KJ; Naylor, AR; Schwalbe, EC; Thompson, MM | 1 |
| Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T | 1 |
| Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L | 1 |
| Arimochi, H; Hagiwara, M; Kataoka, K; Kuwahara, T; Nakayama, H; Ohnishi, Y | 1 |
| Judge, HM; Peters, G; Smith, SM; Storey, RF | 1 |
| Abrahamowicz, M; Austin, PC; Eisenberg, MJ; Humphries, K; Pilote, L; Rahme, E; Tu, JV; Zhou, Z | 1 |
| Almeida, EA; Carneiro, A; Jorge, M; Jorge, PA; Ozaki, MR | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Iwano, C; Matsuyama, K; Matzno, S; Nishikata, M; Yasuda, N | 1 |
| Mc Donnell, CG; Shorten, G; Van Pelt, FN | 1 |
| Corpataux, JM; London, NJ; Naik, J; Porter, KE | 1 |
| Asberg, A; Hermann, M; Holdaas, H; Lemahieu, WP; Maes, BD; Vanrenterghem, Y; Verbeke, K | 1 |
| Boehlen, F; Daali, Y; de Moerloose, P; Fontana, P; Mach, F; Reber, G; Senouf, D; Sigwart, U | 1 |
| Carbonell, T; Freire, E | 1 |
| Blais, L; Bouchard, MH; Collin, J; Dragomir, A; Lalonde, L; Laurier, C; Perreault, S | 1 |
| Dieleman, JP; Dunselman, H; Straus, SM; Sturkenboom, MC; van Herpen, G; van Wijk, MA; van Wyk, JT | 1 |
| Davidson, M | 1 |
| Błaszczyk, J; Ceglińiski, T; Grycewicz, J; Irzmańiski, R; Kowalczyk, E; Kowalski, J; Liban-Gałka, B; Pawlicki, L | 1 |
| Juman, S; Matsuyama, K; Matzno, S; Nagareya-Ishida, N; Nakabayashi, T; Tazuya-Murayama, K; Yamamoto, Y; Yasuda, S | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Fonarow, GC | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Błaszczyk, J; Cegliński, T; Grycewicz, J; Irzmański, R; Kowalczyk, E; Kowalski, J; Liban-Gałka, B; Pawlicki, L | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Bax, JJ; Boersma, E; Dunkelgrün, M; Feringa, HH; Koning, J; Poldermans, D; Schouten, O; van Laanen, JH; van Urk, H; Vidakovic, R | 1 |
| Demyanets, S; Hohensinner, PJ; Huber, K; Kaun, C; Maurer, G; Pammer, J; Pfaffenberger, S; Rega, G; Wojta, J | 1 |
| Foody, JM; Galusha, D; Havranek, EP; Krumholz, HM; Masoudi, FA; Radford, MJ; Rathore, SS | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Otsuka, Y | 1 |
| Bruckert, E; Carreau, V; Chauvenet, M; Faltaos, DW; Giral, P; Hulot, JS; Lechat, P; Urien, S | 1 |
| Berneis, K; Rizzo, M | 1 |
| Plans-Rubió, P | 1 |
| Lachaine, J; Merikle, EP; Rinfret, S; Tarride, JE | 1 |
| Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Brecht, K; Kaufmann, P; Krähenbühl, S; Török, M; Waldhauser, KM; Zahno, A | 1 |
| Chiesa, G; Cippone, V; Conte Camerino, D; De Luca, A; De Vito, D; Didonna, MP; Frigeri, A; Nicchia, GP; Pierno, S; Pisoni, M; Rizzo, C; Scanziani, E; Sirtori, C; Svelto, M | 1 |
| Banach, M; Barylski, M; Grycewicz, J; Irzmański, R; Kowalski, J; Pawlicki, L | 1 |
| Camerino, DC; Camerino, GM; Cippone, V; Giannuzzi, V; Liantonio, A; Pierno, S | 1 |
| Delgado, O; Kaczmarek, I; Meiser, B; Reichart, B; Sadoni, S; Schmöckel, M | 1 |
| Hammervold, T; Howe, PR; Meyer, BJ; Rustan, AC | 1 |
| Altman, JK; Antico, G; Katsoulidis, E; Minucci, S; Platanias, LC; Redig, AJ; Sassano, A; Tallman, MS | 1 |
| Batt, AM; Bertrand-Thiebault, C; Masson, C; Siest, G; Visvikis-Siest, S | 1 |
| Bax, JJ; Davignon, J; Dunkelgrun, M; Feringa, HH; Hoeks, SE; Kastelein, JJ; Poldermans, D; Schouten, O; van Domburg, RT; Vidakovic, R; Welten, GM | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Argenti, A; Berkowitz, JD; Burnham, BS; Dalglish, GA; Evans, MA; Getzel, A; Glersaye, J; Gupton, JT; Holub, JM; Krumpe, K; Lam, KS; Lukens, JR; McCranor, BJ; Miller, RB; Miott, U; O'Toole-Colin, K; Rifat, S; Smith, DC; Taylor, BM; Wilson, DL | 1 |
| Midgley, L; O'Regan, DJ; Porter, KE; Turner, NA | 1 |
| Cappelleri, JC; Dubois, RW; Messerli, FH; Pinto, L; Sichrovsky, T; Tang, SS; Thakker, KM | 1 |
| Asberg, A; Gedde-Dahl, A; Hejazifar, S; Hoel, K; Skottheim, IB | 1 |
| Angelin, B; Davis, MA; Einarsson, C; Eriksson, M; Gustafsson, U; Larsson, L; Omura, S; Parini, P; Rudel, LL; Rudling, M; Sahlin, S; Tomoda, H; Wilson, M | 1 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B | 1 |
| Gawaz, M; Geisler, T; Paterok, M; Zürn, CS | 1 |
| Doggrell, SA | 1 |
| Derdak, Z; Harangi, M; Mirdamadi, HZ; Paragh, G; Seres, I; Sztanek, F | 1 |
| Xiao, H; Yang, CS | 1 |
| Lóopez-Marure, R; Massó, FA; Montaño, LF; Páez, A; Rodríguez, E; Sánchez, CA; Varela, E; Zapata, E | 1 |
| Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S | 1 |
| Bienvenu, AL; Picot, S | 1 |
| Mullangi, R; Srinivas, NR | 1 |
| Freedland, SJ; Goldberg, KC; Hamilton, RJ; Platz, EA | 1 |
| Arora, P; Devereaux, PJ; Mills, EJ; Perri, D; Rachlis, B; Wu, P | 1 |
| Pedersen, TR | 1 |
| Hoffmann, M; Nowosielski, M | 1 |
| Shen, J; Zhang, Q; Zhang, RY | 1 |
| Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S | 1 |
| Abel, T; Fehér, J | 1 |
| Bianco, G; Camerino, GM; Cippone, V; Conte Camerino, D; De Luca, A; Desaphy, JF; George, AL; Kunic, JD; Liantonio, A; Pierno, S; Rolland, JF | 1 |
| Barbieri, M; Bertolini, S; Canonica, GW; Descalzi, D; Folli, C; Gamalero, C; Passalacqua, G; Riccio, AM; Scordamaglia, F | 1 |
| Hoskova, L; Kautzner, J; Kubanek, M; Malek, I; Podzimkova, M; Skalicka, B; Vymetalova, Y | 1 |
| Jin, D; Kim, DH; Kim, SK; Lee, KJ; Li, JH; Qi, XF; Teng, YC; Yoon, YS | 1 |
| Zdebik, AA | 1 |
| Bonkovsky, HL; Russo, MW; Scobey, M | 1 |
| Adámek, T; Alusik, S; Lejsková, M; Paluch, Z | 1 |
| Abrecht, L; Eshtehardi, P; Haeberli, A; Hess, OM; Meier, B; Schmidlin, K; Wenaweser, P; Windecker, S; Zwahlen, M | 1 |
| Kalonia, H; Kumar, A; Kumar, P | 1 |
| Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A | 1 |
| Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M | 1 |
| Ashour, S; Bahbouh, M; Khateeb, M | 1 |
| Boutros, PC; Clendening, JW; Goard, CA; Martirosyan, A; Mather, RG; Penn, LZ; Sharom, FJ; Vinepal, B | 1 |
| Akhtar, S; Al-Sagair, OA; Arif, JM; Salman Khan, M | 1 |
| D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE | 1 |
| Barone, E; Butterfield, DA; Mancuso, C | 1 |
| Chang, BC; Chen, LM; Fang, PH; Ren, HZ; Shan, CY; Wang, Y; Yang, JH; Zheng, MY | 1 |
| Chupka, J; Duignan, DB; El-Kattan, AF; Feng, B; Goosen, TC; Litchfield, J; Rotter, CJ; Varma, MV; Whalen, KM | 1 |
| Haygood, TM; Jonasch, E; Manoukian, GE; Qiao, W; Tannir, NM; Tu, SM | 1 |
| Czuczwar, SJ; Luszczki, JJ; Stepien, KM; Tomaszewski, M | 1 |
| Burzynska, B; Gora, M; Hoser, G; Iwanicka-Nowicka, R; Kiliszek, M; Koblowska, M; Kotlinski, M; Leszczynska, A; Plochocka, D; Rawa, K; Szkopinska, A | 1 |
| Altman, JK; Gordon, LI; Platanias, LC; Sassano, A | 1 |
| Hohendorff, B; Mühldorfer-Fodor, M; Prommersberger, KJ; Schmitt, R; Wagner, M | 1 |
| Dandri, M; Kah, J; Keller, AD; Montalbano, R; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Volz, T; Wüstenberg, A | 1 |
| Aukrust, P; Breland, UM; Hagelsteen, K; Halvorsen, B; Haraldsen, G; Hol, J; Kasprzycka, M; Otterdal, K; Pedersen, TM; Ranheim, T; Stang, E | 1 |
| Dimbil, M; Golomb, BA; Hoffman, KB; Kraus, C | 1 |
| Ishikawa, T; Kinoshita, M; Mashimo, Y; Numakura, M; Teramoto, T | 1 |
| Kalonia, H; Kumar, A; Kumar, P; Mishra, J; Vashist, A | 1 |
| Cai, DQ; Kim, CS; Kim, DH; Kim, SK; Lee, KJ; Qi, XF; Qin, JW; Wu, Z; Yu, YH; Zheng, L | 1 |
| Campbell, SM; Godman, B; Gustafsson, LL; Pichetti, S; Sermet, C | 1 |
| Bergström, H; Björkhem-Bergman, L; Ekström, L; Eriksson, M; Johansson, M; Parini, P; Rane, A | 1 |
| Farkas, Z; Gácser, A; Grózer, Z; Márki-Zay, J; Nagy, K; Pfeiffer, I; Szenzenstein, J; Vágvölgyi, C | 1 |
| Catapano, AL; Corrao, G; Ibrahim, B; Mancia, G; Merlino, L; Nicotra, F; Pasini, TS; Zambon, A | 1 |
| Burzynska, B; Danikiewicz, W; Gora, M; Kaminska, J; Leszczynska, A; Maciejak, A; Odolczyk, N; Plochocka, D; Siedlecka, J; Sojka, M; Swiezewska, E; Sygitowicz, G; Szkopinska, A; Tulacz, D; Warchol, I; Wysocka-Kapcinska, M | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, EY; Huh, KH; Kang, ES; Kim, MS; Kim, YS; Kwon, O; Lee, HC; Wang, HJ | 1 |
| Bátai-Konczos, A; Jemnitz, K; Kékesi, O; Kis, E; Szabó, K; Szabó, M; Veres, Z | 1 |
| Cao, YJ; Du, HP; Hu, LF; Li, J; Liu, CF; Liu, H; Wang, F; Wang, YL; Xu, R; Xu, Y; You, SJ | 1 |
| Assassi, AL; Auzerie, J; Gaudin, K; Hamon, T; Perovitch, P; Roy, CE | 1 |
| Gandhi, HP; Patel, SS; Rathod, SP; Trivedi, JI; Variya, BC | 1 |
| Doricakova, A; Dvorak, Z; Korhonova, M | 1 |
| Björkhem-Bergman, L; Diczfalusy, U; Eriksson, M; Nylén, H; Parini, P | 1 |
| Banach, M; Bittner, V; Hovingh, GK; Kastelein, JJ; Lip, GY; Mikhailidis, DP; Ray, K; Rysz, J; Sahebkar, A; Serban, C; Undas, A; Ursoniu, S; Watts, GF | 1 |
| Chang, YH; Chien, LN; Chuang, MT; Lin, CF; Liu, JC | 1 |
| Bonilla, H; Butt, AA; Chung, RT; Simon, TG; Yan, P | 1 |
| Cheng, Z; Fu, SW; Hu, B; Ruan, LY; Wang, Y; Zheng, JN; Zheng, MH; Zhou, YY; Zhu, GQ | 1 |
| Hwang, HJ; Kim, KS; Lee, EJ; Song, KJ | 1 |
| Corkum, A; Fisher, J; Minard, LV; Saleh, A; Sketris, I; Zhang, Y | 1 |
| Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y | 1 |
| Bonsu, KO; Buabeng, KO; Kadirvelu, A; Owusu, IK; Reidpath, DD | 1 |
| Anoopkumar-Dukie, S; Davey, AK; McFarland, AJ | 1 |
| D'Acunto, WC; Gbelcová, H; Knejzlík, Z; Kolář, M; Repiská, V; Rimpelová, S; Ruml, T; Šáchová, J; Strnad, H; Vítek, L | 1 |
| Apola, A; Kwiecień, A; Maślanka, A; Opoka, W; Stolarczyk, M | 1 |
| Chang, R; Cheng, N; Lu, Y; Teng, Y; Xu, X; Yao, J | 1 |
| Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG | 1 |
| de Fijter, JW; Dekker, FW; Dekkers, OM; Esmeijer, K; Hoogeveen, EK | 1 |
| Lopes, CM; Parks, XX; Qudsi, H; Ronzier, E | 1 |
| Attalah Nee Rezkallah, C; Chen, QM; Thongkum, A; Zhu, C | 1 |
| Adams, SP; Alaeiilkhchi, N; Wright, JM | 1 |
| Arberas-Jiménez, I; Lorenzo-Morales, J; Piñero, JE; Reyes-Batlle, M; Rizo-Liendo, A; Sifaoui, I | 1 |
| Rao, PS; Rao, US | 1 |
| Aksoy, HN; Ceylan, C | 1 |
| Barwiolek, M; Budny, M; Ciarkowska, A; Kozakiewicz, A; Loch, JI; Sokolowska, Z; Wojtczak, A; Wujak, M | 1 |
| Chen, WM; Shia, BC; Wu, SY; Yu, JM | 1 |
| Abdulaziz, O; Ahmad, S; Ali, N; Ali, W; Aljuaid, A; Allahyani, M; Almehmadi, M; Alsaiari, AA; Ullah, A | 1 |
| Filppula, AM; Hirvensalo, P; Keskitalo, J; Kiiski, JI; Lönnberg, KI; Mustaniemi, AL; Niemi, M; Tornio, A | 1 |
| Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF | 1 |
| Adams, SP; Alaeiilkhchi, N; Tasnim, S; Wright, JM | 1 |
36 review(s) available for atorvastatin and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Division; Cytochrome P-450 Enzyme System; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Mevalonic Acid; Pyridines; Pyrroles; Simvastatin | 1999 |
Statin trials in progress: unanswered questions.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
New statins and new doses of older statins.
Topics: Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2001 |
Effective use of statins to prevent coronary heart disease.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin | 2001 |
[The role of HDL in the prevention of cardiovascular events].
Topics: Anticholesteremic Agents; Arteriosclerosis; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Esterases; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipid Peroxidation; Lovastatin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrroles; Simvastatin | 2001 |
Statin therapy--what now?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Patient Selection; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
Synthetic statins: more data on newer lipid-lowering agents.
Topics: Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipids; Pyridines; Pyrroles; Simvastatin | 2001 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Topics: Atorvastatin; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Atorvastatin; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; International Normalized Ratio; Male; Patient Compliance; Pyrroles; Simvastatin; Venous Thrombosis; Warfarin | 2004 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
In-hospital initiation of statin therapy in acute coronary syndromes: maximizing the early and long-term benefits.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Ischemia; Pravastatin; Pyrroles; Syndrome; Treatment Outcome | 2005 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
The clinical relevance of low-density-lipoproteins size modulation by statins.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Particle Size; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutics | 2008 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
[Pleiotropic effects of statins].
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies.
Topics: Atorvastatin; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Indoles; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Ticlopidine | 2009 |
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Confidence Intervals; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk | 2008 |
Drug-induced liver injury associated with statins.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Autoimmunity; Biomarkers; Biopsy; Chemical and Drug Induced Liver Injury; Chronic Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Liver; Liver Diseases; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Risk Assessment; Treatment Outcome; Young Adult | 2009 |
The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials.
Topics: Adult; Aged; Antigens; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Thrombosis; von Willebrand Factor; Young Adult | 2016 |
Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Topics: Atorvastatin; Bayes Theorem; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Neoplasms; Lovastatin; Observational Studies as Topic; Pravastatin; Pyridines; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2016 |
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Diseases; Lipids; Lovastatin; Muscles; Network Meta-Analysis; Patient Safety; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2016 |
Effectiveness of long-term using statins in COPD - a network meta-analysis.
Topics: Atorvastatin; Drug Administration Schedule; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Simvastatin; Time Factors; Treatment Outcome | 2019 |
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment | 2019 |
Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis.
Topics: Atorvastatin; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lovastatin; Network Meta-Analysis; Pravastatin; Proteinuria; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2019 |
Pitavastatin for lowering lipids.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Controlled Before-After Studies; Drug Administration Schedule; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pyridines; Quinolines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sex Factors; Triglycerides | 2020 |
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; Humans; Ischemic Stroke; Metoprolol; Pravastatin; Probucol; Rosuvastatin Calcium; Stroke; Warfarin | 2023 |
Pravastatin for lowering lipids.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug-Related Side Effects and Adverse Reactions; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Infant, Newborn; Pravastatin; Rosuvastatin Calcium | 2023 |
27 trial(s) available for atorvastatin and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Colestipol; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lovastatin; Male; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Policy; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Simvastatin; United States | 1998 |
[Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Indoles; Pyrroles | 1999 |
Lowering effects of four different statins on serum triglyceride level.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1999 |
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Topics: Adolescent; Adult; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lovastatin; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 2001 |
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pravastatin; Pyrroles; Risk; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; United States | 2001 |
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin; Thrombin; Treatment Outcome | 2001 |
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Maximum Tolerated Dose; Middle Aged; Pravastatin; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Single-Blind Method; Treatment Outcome | 2002 |
Time-dependent effect of statins on platelet function in hypercholesterolaemia.
Topics: Adult; Analysis of Variance; Antiporters; Atorvastatin; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2003 |
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lipoproteins; Lovastatin; Male; Middle Aged; Postprandial Period; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2004 |
Plasma antioxidative activity during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention.
Topics: Adult; Antioxidants; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pyrroles | 2004 |
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Topics: Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcineurin Inhibitors; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lactones; Liver; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pravastatin; Pyrroles; Simvastatin; Tacrolimus; Time Factors | 2005 |
[Estimation of antioxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease--effect on antioxidative enzymatic activity].
Topics: Adult; Antioxidants; Atorvastatin; Coronary Artery Disease; Erythrocytes; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Primary Prevention; Pyrroles; Treatment Outcome | 2005 |
[Estimation of antioxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease--effect on lipid peroxidation].
Topics: Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Coronary Artery Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Free Radical Scavengers; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Primary Prevention; Pyrroles; Treatment Outcome | 2005 |
Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention.
Topics: Adult; Atorvastatin; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Male; Middle Aged; Neutrophils; Primary Prevention; Pyrroles; Superoxides; Zymosan | 2006 |
Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.
Topics: Animals; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Dietary Fats; Dietary Fats, Unsaturated; Dietary Supplements; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fish Oils; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipid Metabolism; Lipids; Lipoproteins, IDL; Lipoproteins, VLDL; Male; Middle Aged; Pyridines; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2007 |
Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2.
Topics: Apolipoproteins E; Atorvastatin; Biopsy; Cholesterol; Cholesterol, VLDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Male; Middle Aged; Pyrroles; Receptors, LDL; RNA, Messenger; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2 | 2008 |
[Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina].
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Atorvastatin; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2008 |
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atorvastatin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Prosthesis Design; Pyrroles; Switzerland; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients.
Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke | 2011 |
Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Biomarkers, Tumor; Bone Neoplasms; Bone Remodeling; Carcinoma, Renal Cell; Diphosphonates; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pilot Projects; Pyrroles; Zoledronic Acid | 2011 |
Atorvastatin treatment induces uptake and efflux transporters in human liver.
Topics: Adult; Aged; Atorvastatin; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Male; Membrane Transport Proteins; Middle Aged; Pyrroles; RNA, Messenger; Young Adult | 2013 |
129 other study(ies) available for atorvastatin and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Lovastatin; Male; Naphthalenes; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tumor Cells, Cultured | 1990 |
The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
Topics: Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1997 |
Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells.
Topics: Animals; Apoptosis; Atorvastatin; Carotid Stenosis; Cell Division; Cells, Cultured; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Rabbits; Simvastatin | 1997 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 1998 |
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Benzimidazoles; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Ketoconazole; Kinetics; Lovastatin; Mibefradil; Microsomes, Liver; Oxidoreductases, N-Demethylating; Pyridines; Pyrroles; Simvastatin; Tetrahydronaphthalenes | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
[Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?].
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Dogs; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Contraction; Myocardial Ischemia; Myocardial Stunning; Myocardium; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Cholesterol; Dogs; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Myocardial Reperfusion Injury; Myocardial Stunning; Perfusion; Pyridines; Pyrroles; Random Allocation; Simvastatin; Solubility; Time Factors | 2000 |
Effect of statin therapy on restenosis after coronary stent implantation.
Topics: Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Coronary Angiography; Coronary Disease; Disease-Free Survival; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hyperplasia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Stents; Time Factors; Tunica Intima | 2000 |
Pleiotropic effects of statins in atherosclerosis and diabetes.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Division; Cell Movement; Cells, Cultured; Cholesterol; Cholesterol Esters; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Muscle, Smooth; Pyridines; Pyrroles; Simvastatin | 2000 |
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Topics: Animals; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Microsomes, Liver; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Species Specificity | 2000 |
Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells.
Topics: Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1; Plasminogen Activator Inhibitor 1; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Tissue Plasminogen Activator; Tumor Necrosis Factor-alpha | 2000 |
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
Topics: Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Least-Squares Analysis; Linear Models; Lovastatin; Nonlinear Dynamics; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Tachyphylaxis; Time Factors | 2000 |
Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Male; Middle Aged; Norway; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Simvastatin; Surveys and Questionnaires | 2000 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Models, Economic; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.
Topics: Acute Disease; Apoptosis; Atorvastatin; Cell Division; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia, Myeloid; Lovastatin; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Pyrroles; Sensitivity and Specificity; Tumor Cells, Cultured | 2001 |
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
The use over time of statins in coronary patients in an Italian tertiary referral center.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Utilization Review; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2001 |
Safety and efficacy of atorvastatin in heart transplant recipients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Glucocorticoids; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Prednisone; Pyrroles; Retrospective Studies; Treatment Outcome | 2002 |
The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Muscular Diseases; Myositis; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin | 2002 |
A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Models, Economic; Pravastatin; Pyrroles; Simvastatin; United Kingdom | 2003 |
Variable influence of statins on isoprostanes in hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Male; Microfilament Proteins; Middle Aged; Muscle Proteins; Pravastatin; Pyrroles; Retrospective Studies | 2003 |
Toward a role for statins in immunomodulation.
Topics: Adjuvants, Immunologic; Animals; Atorvastatin; Autoimmune Diseases; Cytokines; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2002 |
Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biological Transport; Blotting, Northern; Cell Line; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Luciferases; Macrophages; Mice; Oxygen; Promoter Regions, Genetic; Pyrroles; RNA, Messenger; Simvastatin; Swiss 3T3 Cells; Time Factors; Transcription, Genetic | 2004 |
Class-specific pro-apoptotic effect of statins on human vascular endothelial cells.
Topics: Apoptosis; Atorvastatin; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Fas Ligand Protein; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Membrane Glycoproteins; Metabolic Clearance Rate; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Simvastatin; Umbilical Veins | 2004 |
Update on statins.
Topics: Atorvastatin; Coronary Disease; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukins; Male; Matrix Metalloproteinases; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Tissue Inhibitor of Metalloproteinases; Tumor Necrosis Factor-alpha; Ultrasonography | 2004 |
Inhibitory effect of statins on the proliferation of human breast cancer cells.
Topics: Anticholesteremic Agents; Apoptosis; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Antagonism; Estradiol; Estrogens; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Neoplasms, Hormone-Dependent; Pyrroles | 2004 |
A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Topics: Area Under Curve; Atorvastatin; Biomedical Research; Databases, Bibliographic; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Japan; Pharmacology, Clinical; Pravastatin; Product Labeling; Pyrroles; Quinolines; Simvastatin; United States; United States Food and Drug Administration | 2005 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors | 2005 |
Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileal Diseases; Ileum; Indoles; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Ulcer | 2005 |
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine | 2004 |
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Topics: Aged; Atorvastatin; Cohort Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mortality; Myocardial Infarction; Patient Compliance; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Survival Analysis | 2005 |
[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2005 |
Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry.
Topics: Apoptosis; Atorvastatin; Avidin; Biotin; Cell Line; Cell Separation; Cells, Cultured; Drug Industry; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia; Microscopy, Fluorescence; Necrosis; Pharmaceutical Preparations; Pravastatin; Propidium; Pyridines; Pyrroles; Simvastatin; Time Factors | 2005 |
Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro.
Topics: Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; In Vitro Techniques; Indoles; Microsomes, Liver; Midazolam; Pyrroles | 2005 |
The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.
Topics: Atorvastatin; Cell Division; Cell Movement; Chemotaxis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Myocytes, Smooth Muscle; Pravastatin; Pyridines; Pyrroles; Saphenous Vein; Simvastatin | 2005 |
Not all statins interfere with clopidogrel during antiplatelet therapy.
Topics: Adult; Atorvastatin; Chromatography, High Pressure Liquid; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2005 |
Binding thermodynamics of statins to HMG-CoA reductase.
Topics: Atorvastatin; Binding Sites; Calorimetry; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Protein Binding; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Thermodynamics | 2005 |
Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.
Topics: Atorvastatin; Cardiovascular Diseases; Drug Prescriptions; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pyrroles; Regression Analysis; Time Factors | 2005 |
Differences between statins on clinical endpoints: a population-based cohort study.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Endpoint Determination; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Netherlands; Pravastatin; Pyridines; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein.
Topics: Animals; Apoptosis; Atorvastatin; Caspase 8; Cell Line; Fatty Acids, Monounsaturated; Flow Cytometry; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Lipids; Microscopy, Fluorescence; Myoblasts, Skeletal; Protein Prenylation; Pyridines; Pyrroles; ras Proteins; Rats; rho GTP-Binding Proteins; Signal Transduction | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth.
Topics: Aged; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Atorvastatin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Netherlands; Population Surveillance; Pyrroles; Retrospective Studies; Simvastatin; Time Factors; Ultrasonography | 2006 |
Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro.
Topics: Adult; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Cells, Cultured; DNA Fragmentation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myeloid Cell Leukemia Sequence 1 Protein; Myocytes, Cardiac; Neoplasm Proteins; Pravastatin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Messenger; Simvastatin | 2006 |
Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.
Topics: Age Factors; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Drug Prescriptions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Myocardial Infarction; Odds Ratio; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Inhibitory effects of statins on human monocarboxylate transporter 4.
Topics: Animals; Atorvastatin; Basigin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lactic Acid; LLC-PK1 Cells; Lovastatin; Monocarboxylic Acid Transporters; Muscle Proteins; Pyridines; Pyrroles; Simvastatin; Swine; Transfection | 2006 |
Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.
Topics: Adolescent; Adult; Aged; Atorvastatin; Child; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Male; Middle Aged; Models, Biological; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain | 2006 |
Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrroles; Quebec; Registries; Retrospective Studies; Simvastatin | 2006 |
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Biopsy; Brachytherapy; Cause of Death; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Retrospective Studies; Simvastatin; Survival Analysis | 2006 |
Toxicity of statins on rat skeletal muscle mitochondria.
Topics: Animals; Apoptosis; Atorvastatin; Cytochromes c; DNA Fragmentation; Fatty Acids; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Potentials; Mitochondria, Muscle; Mitochondrial Membranes; Muscle, Skeletal; Oxygen; Pravastatin; Pyridines; Pyrroles; Rats; Simvastatin | 2006 |
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study.
Topics: Action Potentials; Animals; Aquaporin 4; Atorvastatin; Body Weight; Chloride Channels; Dose-Response Relationship, Drug; Eating; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Diseases; Lipids; Male; Membrane Potentials; Muscle Contraction; Muscle Fibers, Fast-Twitch; Muscle, Skeletal; Muscular Diseases; Myosin Heavy Chains; Organ Size; Pyrroles; Rats; Rats, Wistar; Rhabdomyolysis; Time Factors | 2006 |
Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system.
Topics: Animals; Atorvastatin; Caffeine; Calcium; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Homeostasis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Manganese; Mitochondria; Muscle Fibers, Skeletal; Muscle Strength; Muscle, Skeletal; Pyrroles; Rats; Rats, Wistar; Sarcolemma; Sarcoplasmic Reticulum | 2007 |
Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase.
Topics: Adult; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
Suppressive effects of statins on acute promyelocytic leukemia cells.
Topics: Atorvastatin; cdc42 GTP-Binding Protein; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; Pyrroles; rac1 GTP-Binding Protein; Tretinoin | 2007 |
Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line.
Topics: Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blotting, Western; Cell Line; Cell Proliferation; Cell Survival; Constitutive Androstane Receptor; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Endothelial Cells; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pregnane X Receptor; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Glucocorticoid; Receptors, Steroid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saphenous Vein; Transcription Factors; Up-Regulation | 2007 |
Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
Topics: Aged; Atorvastatin; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Substance Withdrawal Syndrome; Troponin T; Vascular Surgical Procedures | 2007 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Lipid-lowering effects of ethyl 2-phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in rodents.
Topics: Acetophenones; Animals; Atorvastatin; Carboxylic Acids; Cholesterol, HDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Mice; Pyrroles; Rats; Rats, Sprague-Dawley | 2004 |
Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Topics: Atorvastatin; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pyrroles; Saphenous Vein; Simvastatin | 2007 |
Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.
Topics: Acids; Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Stability; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; Lactones; Microscopy, Fluorescence; Molecular Structure; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Satellite Cells, Skeletal Muscle; Simvastatin; Structure-Activity Relationship | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides | 2008 |
[Influence of statins on the antiplatelet effect of clopidogrel and on cardiovascular outcome in patients after coronary intervention].
Topics: Atorvastatin; Clopidogrel; Coronary Disease; Coronary Stenosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Simvastatin; Stents; Ticlopidine | 2008 |
The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.
Topics: Aryldialkylphosphatase; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Pyrroles; Simvastatin | 2008 |
Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Atorvastatin; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Proliferation; DNA Replication; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Potential, Mitochondrial; Necrosis; Oxidative Stress; Pyrroles; Reactive Oxygen Species; Simvastatin | 2008 |
Statins alone are ineffective in cerebral malaria but potentiate artesunate.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Atorvastatin; Disease Models, Animal; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Malaria, Cerebral; Malaria, Falciparum; Mice; Neuroprotective Agents; Pravastatin; Pyrroles; Simvastatin | 2008 |
The influence of statin medications on prostate-specific antigen levels.
Topics: Aged; Atorvastatin; Biomarkers, Tumor; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Linear Models; Longitudinal Studies; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Risk Assessment; Simvastatin; Veterans | 2008 |
Intensive lipid-lowering therapy for patients with aortic stenosis.
Topics: Aortic Valve Stenosis; Atorvastatin; Clinical Trials as Topic; Disease Progression; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
DFT study on hydroxy acid-lactone interconversion of statins: the case of atorvastatin.
Topics: Atorvastatin; Carboxylic Acids; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydrogen-Ion Concentration; Hydrolysis; Hydroxy Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lactones; Pyrroles; Quantum Theory | 2008 |
[Statin therapy and muscle disorders].
Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression.
Topics: Action Potentials; Animals; Atorvastatin; Benzophenanthridines; Calcium; Cell Line; Chloride Channels; Chlorides; Dose-Response Relationship, Drug; Down-Regulation; Electromyography; Enzyme Activation; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Muscle, Skeletal; Patch-Clamp Techniques; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Transfection | 2009 |
Effect of statins on fibroblasts from human nasal polyps and turbinates.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cell Division; Depression, Chemical; Drug Evaluation, Preclinical; Fatty Acids, Monounsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Nasal Polyps; Pyrroles; Simvastatin; Turbinates | 2008 |
Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heart Transplantation; Heptanoic Acids; Humans; Immunosuppressive Agents; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Tacrolimus; Treatment Outcome; Triglycerides | 2009 |
Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-gamma in HaCaT cells, a human keratinocyte cell line.
Topics: Atorvastatin; Cell Line; Chemokine CCL22; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interferon-gamma; Keratinocytes; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Pyrroles; Signal Transduction; Simvastatin; Th2 Cells | 2009 |
Statins and fibrate target ClC-1 - from side effects to CLC pharmacology.
Topics: Action Potentials; Animals; Atorvastatin; Calcium; Chloride Channels; Chlorides; Down-Regulation; Enzyme Activation; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Muscle, Skeletal; Protein Kinase C; Pyrroles; RNA, Messenger | 2009 |
The inhibitory effect of statins on urinary 11-dehydrothromboxane levels.
Topics: Aged; Aspirin; Atorvastatin; Biomarkers; Blood Glucose; Blood Platelets; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Czech Republic; Down-Regulation; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Simvastatin; Thromboxane B2; Time Factors; Treatment Outcome; Triglycerides | 2010 |
Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats.
Topics: Analysis of Variance; Animals; Atorvastatin; Behavior, Animal; Body Weight; Corpus Striatum; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Peroxidation; Male; Mitochondria; Motor Activity; Neuroprotective Agents; Neurotoxicity Syndromes; Nitrites; Oxidative Stress; Pyrroles; Quinolinic Acid; Rats; Rats, Wistar; Rotarod Performance Test; Simvastatin; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2011 |
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides | 2011 |
A novel use of oxidative coupling reactions for determination of some statins (cholesterol-lowering drugs) in pharmaceutical formulations.
Topics: Atorvastatin; Chemistry, Pharmaceutical; Dosage Forms; Excipients; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Molecular Structure; Oxidation-Reduction; Oxidative Coupling; Pravastatin; Pyrroles; Spectrophotometry | 2011 |
Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Ovarian Neoplasms; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Tumor Cells, Cultured | 2010 |
Protective effect of dietary tocotrienols against infection and inflammation-induced hyperlipidemia: an in vivo and in silico study.
Topics: Administration, Oral; Animals; Atorvastatin; Cholesterol; Cricetinae; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipid Metabolism; Lipoproteins, LDL; Male; Molecular Structure; Pyrroles; Tocotrienols | 2011 |
Statins and prostate cancer diagnosis and grade in a veterans population.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biomarkers, Tumor; Cholesterol; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lipids; Lovastatin; Male; Middle Aged; Multivariate Analysis; New England; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Risk Assessment; Severity of Illness Index; Simvastatin; Veterans | 2011 |
Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders.
Topics: Alzheimer Disease; Animals; Atorvastatin; Cholesterol; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Neurodegenerative Diseases; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2011 |
[Research on the effect of statins on insulin secretion from pancreatic islet in rats and its mechanisms].
Topics: Animals; Atorvastatin; Cells, Cultured; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Insulin; Insulin Secretion; Islets of Langerhans; Male; Pyrroles; Rats; Rats, Wistar | 2011 |
pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.
Topics: Atorvastatin; Caco-2 Cells; Cell Line; Chromatography, Liquid; Estrone; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Intestinal Absorption; Organic Anion Transporters; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Tandem Mass Spectrometry | 2011 |
The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model.
Topics: Animals; Anticonvulsants; Atorvastatin; Brain; Carbamazepine; Disease Models, Animal; Drug Interactions; Electroshock; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Indoles; Male; Memory; Mice; Motor Activity; Phenytoin; Pyrroles; Seizures; Valproic Acid | 2012 |
Different statins produce highly divergent changes in gene expression profiles of human hepatoma cells: a pilot study.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Computational Biology; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Profiling; Gene Expression Regulation; Genome, Human; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Metabolic Networks and Pathways; Mevalonic Acid; Oligonucleotide Array Sequence Analysis; Pilot Projects; Principal Component Analysis; Pyrroles; Simvastatin | 2011 |
Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation.
Topics: Antineoplastic Agents; Atorvastatin; Cell Differentiation; Cell Line, Tumor; Chemokine CCL3; Chemokine CCL4; Drug Synergism; Enzyme Activation; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Leukemic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Indoles; Leukemia, Promyelocytic, Acute; Protein Kinase C-delta; Proteolysis; Pyrroles; RNA Interference; Signal Transduction; Tretinoin | 2012 |
[Focal myositis as a side effect of antilipidemics - 2 patients with involvement of the forearm].
Topics: Anticholesteremic Agents; Atorvastatin; Bezafibrate; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Forearm; Heptanoic Acids; Humans; Hyperlipidemias; Image Interpretation, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pyrroles | 2012 |
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cholesterol; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Suppressor Protein p53 | 2012 |
Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies.
Topics: Atorvastatin; Cell Compartmentation; Chemokine CXCL1; Chemokines; E-Selectin; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1beta; Intracellular Space; Multivesicular Bodies; Pravastatin; Prenylation; Pyrroles; Simvastatin; Solubility; Subcellular Fractions; Tetraspanin 30 | 2012 |
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Topics: Atorvastatin; Databases, Factual; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tendons; United States; United States Food and Drug Administration | 2012 |
Critical promoter region for statin-induced human endothelial nitric oxide synthase (eNOS) transcription in EA.hy926 cells.
Topics: Atorvastatin; Cells, Cultured; Fatty Acids, Monounsaturated; Fluvastatin; Genes, Reporter; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Nitric Oxide Synthase Type III; Plasmids; Promoter Regions, Genetic; Pyrroles; Quinolines; RNA, Messenger; Transcription, Genetic | 2013 |
Protective effect of HMG CoA reductase inhibitors against running wheel activity induced fatigue, anxiety like behavior, oxidative stress and mitochondrial dysfunction in mice.
Topics: Animals; Anxiety; Atorvastatin; Behavior, Animal; Brain; Catalase; Electron Transport Chain Complex Proteins; Fatigue Syndrome, Chronic; Fatty Acids, Monounsaturated; Fluvastatin; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Peroxidation; Male; Maze Learning; Mice; Mitochondria; Motor Activity; Nitrites; Oxidative Stress; Physical Exertion; Pyrroles; Running; Swimming; Time Factors | 2012 |
HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
Topics: Acetylcysteine; Acyl Coenzyme A; Animals; Antioxidants; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; DNA Fragmentation; Extracellular Signal-Regulated MAP Kinases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lymphoma; Membrane Potential, Mitochondrial; Mevalonic Acid; Mice; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Reactive Oxygen Species; Signal Transduction; Simvastatin | 2013 |
Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus; Drug Prescriptions; Drugs, Generic; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; France; General Practitioners; Heart Diseases; Heptanoic Acids; Humans; Indoles; Lipid Metabolism Disorders; Male; Middle Aged; Models, Statistical; Practice Patterns, Physicians'; Pravastatin; Prescription Drugs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Differential sensitivity of the species of Candida parapsilosis sensu lato complex against statins.
Topics: Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Candida; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Indoles; Microbial Sensitivity Tests; Microbiological Techniques; Pyrroles; Sensitivity and Specificity | 2013 |
Long-term use of statins reduces the risk of hospitalization for dementia.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Case-Control Studies; Dementia; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Italy; Logistic Models; Male; Middle Aged; Pravastatin; Pyrroles; Risk; Simvastatin; Time Factors | 2013 |
The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.
Topics: Atorvastatin; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fungal Proteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoenzymes; Mevalonic Acid; Organisms, Genetically Modified; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Saccharomyces cerevisiae; Simvastatin; Sterols; Sulfonamides; Terpenes | 2013 |
HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Immunosuppressive Agents; Incidence; Indoles; Kidney Transplantation; Male; Middle Aged; Pyrroles; Renal Insufficiency | 2014 |
Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes.
Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Bilirubin; Biological Transport; Cell Culture Techniques; Cells, Cultured; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Pravastatin; Pyrimidines; Pyrroles; Rats; Rosuvastatin Calcium; Sulfonamides | 2014 |
Statins upregulate cystathionine γ-lyase transcription and H2S generation via activating Akt signaling in macrophage.
Topics: Animals; Atorvastatin; Cell Line; Cystathionine gamma-Lyase; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydrogen Sulfide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Macrophages; Mice; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; RNA, Messenger; Signal Transduction; Up-Regulation | 2014 |
Green analytical method development for statin analysis.
Topics: Acetonitriles; Atorvastatin; Chromatography, High Pressure Liquid; Ethanol; Fatty Acids, Monounsaturated; Fluvastatin; Green Chemistry Technology; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Pyrroles; Solubility; Solvents | 2015 |
Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies.
Topics: Adenosine Triphosphatases; Animals; Atorvastatin; Blood Glucose; Cardiotonic Agents; Catalase; Cholesterol; Fatty Acids, Monounsaturated; Fluvastatin; Glutathione; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoproterenol; Male; Myocardial Infarction; Myocardium; Necrosis; Pravastatin; Rats, Wistar; Rosuvastatin Calcium; Simvastatin; Superoxide Dismutase; Triglycerides | 2015 |
Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes.
Topics: Adult; Aged; Atorvastatin; Cell Line, Tumor; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Enzyme Induction; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hepatocytes; Humans; Indoles; Male; Middle Aged; Pregnane X Receptor; Receptors, Steroid; Rosuvastatin Calcium; Stereoisomerism | 2015 |
Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations.
Topics: Atorvastatin; Biomarkers; Cholesterol; Cytochrome P-450 CYP3A; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gallstones; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Sweden | 2016 |
Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study.
Topics: Aged; Atorvastatin; Case-Control Studies; Comorbidity; Diabetes Mellitus; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Indoles; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pneumonia; Protective Factors; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Taiwan | 2016 |
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fibrosis; Fluvastatin; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged | 2016 |
Effectiveness of atorvastatin in suppressing MUC5AC gene expression in human airway epithelial cells.
Topics: Atorvastatin; Cell Line, Tumor; Cell Membrane; Cholesterol; Epithelial Cells; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1beta; Lovastatin; MAP Kinase Signaling System; Mucin 5AC; RNA, Messenger; Simvastatin | 2016 |
Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis.
Topics: Aged; Aged, 80 and over; Atorvastatin; Clinical Trials as Topic; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Interrupted Time Series Analysis; Lovastatin; Male; Nova Scotia; Pravastatin; Prescription Drugs; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2016 |
Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Black People; Cardiomyopathy, Dilated; Cardiovascular Diseases; Cause of Death; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Fatty Acids, Monounsaturated; Fluvastatin; Ghana; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Mortality; Multivariate Analysis; Probability; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2017 |
Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells.
Topics: Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Cell Proliferation; Chronic Disease; Dinoprostone; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Interleukin-1beta; Lipids; Lipopolysaccharides; Microglia; Monocytes; Nitric Oxide; Pravastatin; Quinolines; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; THP-1 Cells; Tumor Necrosis Factor-alpha | 2017 |
Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Line, Tumor; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Profiling; Gene Expression Regulation; Green Fluorescent Proteins; Humans; Indoles; Insulin-Secreting Cells; Lovastatin; Mevalonic Acid; Microarray Analysis; Mutation; Polyisoprenyl Phosphates; Protein Prenylation; Protein Transport; Proto-Oncogene Proteins p21(ras); Recombinant Fusion Proteins; Sesquiterpenes; Signal Transduction; Simvastatin | 2017 |
Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures.
Topics: Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry; Valsartan | 2017 |
Statin-specific inhibition of Rab-GTPase regulates cPKC-mediated IKs internalization.
Topics: Animals; Atorvastatin; Cells, Cultured; Fluvastatin; HEK293 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocytes, Cardiac; Potassium Channels, Voltage-Gated; Protein Kinase C; rab GTP-Binding Proteins; Rats; Rosuvastatin Calcium; Simvastatin | 2019 |
Resveratrol for protection against statin toxicity in C2C12 and H9c2 cells.
Topics: Animals; Atorvastatin; Caspase 3; Caspase 7; Cell Line; Cell Survival; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Myoblasts; Pravastatin; Protective Agents; Rats; Resveratrol; Signal Transduction; Simvastatin | 2020 |
Fluvastatin and atorvastatin induce programmed cell death in the brain eating amoeba Naegleria fowleri.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Atorvastatin; Brain; Cell Line; Cell Membrane; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mitochondria; Naegleria fowleri; Reactive Oxygen Species | 2020 |
Statins decrease the expression of c-Myc protein in cancer cell lines.
Topics: Atorvastatin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Neoplasms; Proto-Oncogene Proteins c-myc; Simvastatin | 2021 |
Comparison of the Effects of Statins on A549 Nonsmall-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out.
Topics: A549 Cells; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Lung Neoplasms; Pravastatin; Rosuvastatin Calcium; Simvastatin; Spectroscopy, Fourier Transform Infrared | 2021 |
Assessing the Interactions of Statins with Human Adenylate Kinase Isoenzyme 1: Fluorescence and Enzyme Kinetic Studies.
Topics: Adenylate Kinase; Amino Acid Sequence; Atorvastatin; Circular Dichroism; Fluvastatin; Geobacillus stearothermophilus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitory Concentration 50; Isoenzymes; Kinetics; Ligands; Molecular Docking Simulation; Pravastatin; Protein Binding; Recombinant Proteins; Rosuvastatin Calcium; Sequence Alignment; Simvastatin; Spectrometry, Fluorescence; Spectrophotometry; Static Electricity; Temperature | 2021 |
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Primary Prevention; Rosuvastatin Calcium; Simvastatin | 2023 |
Atorvastatin and Fluvastatin Potentiate Blood Pressure Lowering Effect of Amlodipine through Vasorelaxant Phenomenon.
Topics: Amlodipine; Animals; Atorvastatin; Blood Pressure; Calcium; Calcium Channel Blockers; Calcium Channels; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Potassium Chloride; Rabbits; Rats; Rats, Wistar; Vasodilator Agents; Verapamil | 2023 |
Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 CYP2C9; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Neoplasm Proteins; Pharmacogenetics; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2023 |